|
|
|
| Effect of Aidi Injection combined with chemotherapy scheme in the treatment of advanced colorectal cancer |
| LYU Xiazhi |
| Ward One, Department of Medical Oncology, Lu'an Hospital Affiliated to Anhui Medical University, Anhui Province, Lu'an 237000, China |
|
|
|
Abstract Objective To explore the effect of the Aidi Injection combined with chemotherapy scheme in the treatment of advanced colorectal cancer. Methods From June 2013 to June 2016, the clinical data of 70 patients with advanced colorectal cancer treated in Lu'an Hospital Affiliated to Anhui Medical University were retrospectively analyzed, patients were divided into control group and observation group according to the different methods of treatment, each group of 35 cases. The control group was treated by the standard chemotherapy of Oxaliplatin combined with Capecitabine, while the observation group was treated by Aidi Injection on the basis of the treatment of control group. The clinical efficacy of the two groups was compared; the quality of life was assessed before and after treatment by Karnofsky performance status (KPS) score, the improvement of quality of life after treatment was observed; the occurrence of adverse reactions of the two groups was compared. Results The effective rate of the observation group was higher than that of the control group (71.43% vs 60.00%), the difference was statistically significant (P ＜ 0.05). After treatment, the improvement of KPS score in observation group was better than that of the control group, the difference was statistically significant (P ＜ 0.05). The degree of white blood cells decline of the observation group was obviously lower than that of the control group (P ＜ 0.05); the severity of platelet decline, gastrointestinal reaction, neurotoxicity were lighter than those of the control group, but there were no statistically significant differences between the two groups (P ＞ 0.05). Conclusion The effect of Aidi Injection combined with chemotherapy scheme in the treatment of advanced colorectal cancer is significantly better than that of the pure chemotherapy, with less adverse reactions, which can obviously improve the quality of life, and it is worthy of clinical popularization and application.
|
|
|
|
|
|
[1] 代珍，郑荣寿，邹小农，等.中国结直肠癌发病趋势分析和预测[J].中华预防医学杂志，2012，46（7）：598-603.
[2] 朱 广媛，李东华，张树范，等.艾迪注射液的临床研究进展[J].中医药学报，2010，38（1）：123-127.
[3] 朱世杰，贾立群，李佩文，等.艾迪注射液抑制肿瘤新生血管形成的实验研究[J].中国实验方剂学杂志，2008，14（11）：55-57.
[4] 李刚，叶平江，应晓江，等.艾迪联合FOLFIRI方案治疗晚期结直肠癌患者的疗效研究[J].中华全科医学，2015， 13（9）：1414-1416.
[5] 席青，王建清，常小红，等.艾迪注射液在肺癌治疗中的研究进展[J].中国医药导报，2014，11（4）：163-165.
[6] 黄文，曾茹雪，钟辉，等.艾迪注射液对肝癌患者TACE术后血清炎性因子及免疫功能的影响[J].实用癌症杂志，2015，30（5）：658-661.
[7] 付建红，高湛，翟旭华，等.艾迪注射液联合化疗用于老年女性卵巢癌术后辅助治疗的疗效评价[J].中国老年学杂志，2013，33（16）：3973-3975.
[8] 陈耐华.RECIST1.1标准和RECIST1.0标准对大肠癌肝转移疗效评价的比较[J].中国当代医药，2015，22（32）：63-65.
[9] 于金明，徐忠法．肿瘤临床通鉴[M].济南：山东科学技术出版社，2004：1335-1338．
[10] 王钛，薛明道，金智华，等.去甲斑蝥素片的制备工艺及其含量测定[J].中国当代医药，2016，23（3）：86-88，92.
[11] 王勇，刘琴，朱紫结，等.艾迪注射液对人肺腺癌A549细胞放疗敏感性的增加作用及其机制[J].中国中西医结合急救杂志，2015，22（6）：582-586.
[12] 李贞，于广计，李强，等.艾迪注射液联合化疗治疗晚期结直肠癌疗效观察[J].浙江中西医结合杂志，2011，21（6）：397-398.
[13] 吴亭，李日彩.FOLFOX7方案联合艾迪注射液治疗晚期胃癌的效果及毒副反应[J].广东医学，2016，37（3）：438-440.
[14] 刘涛，马铁英.艾迪注射液联合化疗治疗晚期大肠癌的临床观察[J].中国误诊学杂志，2009，9（12）：2849-2850.
[15] 杜芳，王德林，曹玉娟，等.晚期结直肠癌在化疗联合艾迪注射液治疗的效果观察[J].中医临床研究，2015，7（33）：129-130.
[16] 张金娟，张贵林.艾迪注射液对裸鼠人胃癌移植瘤血管生成的影响[J].山东医药，2010，50（47）：34-35.
[17] 李涛，王涛，张锡朋，等.艾迪注射液对结肠癌裸鼠移植瘤生长的抑制作用及对COX-2、VEGF、MMP-9蛋白表达的影响[J].中国老年学杂志，2013，33（16）：3911-3912.
[18] 徐晓莉，王钦，罗佳，等.去甲斑蝥酸钠对人胃癌SGC-7901细胞增殖的影响[J].中国老年学杂志，2016，36（9）：2074-2075.
[19] 杨尚君，罗治彬，张波，等.斑蝥酸钠对肝癌细胞HepG2增殖抑制作用的研究[J].西部医学，2011，23（6）：1007-1009.
[20] 王鸿彪，林英城.人参皂贰Rg3 抗肿瘤作用研究进展[J].医学综述，2009，15（3）：323-326.
[21] 刘明华，任美萍，陈健平，等.黄蔑皂昔抗肿瘤活性研究[J].中药药理与临床，2009，25（2）：68-70.
[22] 杜佳新，顾玉红，张博，等.刺五加有效成分的抗肿瘤作用研究与评价[J].中国医院用药评价与分析，2010，10（3）：199-200.
[23] 徐晓军，石淑文，汤永民，等.人参皂苷Rh2抗白血病多药耐药细胞K562/VCR作用研究[J].中草药，2010，41（07）：113.
[24] 高尔云，张丰林.艾迪注射液在中晚期肺癌患者中的应用价值及对生活质量的影响1-1135[J].中国当代医药，2014，21（25）：107-109.
[25] 戴伟华，刘小平，龚毅，等.艾迪注射液联合TACE术治疗原发性肝癌的临床观察[J].中国医药导报，2010，7（22）：105-106. |
|
|
|
